SMAD4 and ovarian cancer: Since we previously demonstrated that aberrant TGF-β/SMAD4 signaling in ovarian cancer led to epigenetic silencing of its downstream targets29, 34, we further examined whether such “signaling-mediated epigenetic silencing”22 exists in gastric cancer (GC), through aberrant activation of JAK/STAT signaling.